Drugs / AD-2022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06448962 | Oct 2020 → Nov 2021 | essential hypertension, hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06448962 ↗ |
| Route | Oral | “PO, Once daily(QD), 8weeks” NCT06448962 ↗ |